PT3864009T - Inibidores da tyk2 quinase - Google Patents

Inibidores da tyk2 quinase

Info

Publication number
PT3864009T
PT3864009T PT197940950T PT19794095T PT3864009T PT 3864009 T PT3864009 T PT 3864009T PT 197940950 T PT197940950 T PT 197940950T PT 19794095 T PT19794095 T PT 19794095T PT 3864009 T PT3864009 T PT 3864009T
Authority
PT
Portugal
Prior art keywords
kinase inhibitors
tyk2 kinase
tyk2
inhibitors
kinase
Prior art date
Application number
PT197940950T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Sareum Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sareum Ltd filed Critical Sareum Ltd
Publication of PT3864009T publication Critical patent/PT3864009T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT197940950T 2018-10-08 2019-10-07 Inibidores da tyk2 quinase PT3864009T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1816369.1A GB201816369D0 (en) 2018-10-08 2018-10-08 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
PT3864009T true PT3864009T (pt) 2025-04-23

Family

ID=64397425

Family Applications (1)

Application Number Title Priority Date Filing Date
PT197940950T PT3864009T (pt) 2018-10-08 2019-10-07 Inibidores da tyk2 quinase

Country Status (18)

Country Link
US (1) US12187716B2 (enExample)
EP (1) EP3864009B1 (enExample)
JP (1) JP7383030B2 (enExample)
KR (1) KR102844196B1 (enExample)
CN (1) CN113056456B (enExample)
AU (1) AU2019359320B2 (enExample)
BR (1) BR112021006424A2 (enExample)
CA (1) CA3111049A1 (enExample)
DK (1) DK3864009T3 (enExample)
ES (1) ES3021420T3 (enExample)
FI (1) FI3864009T3 (enExample)
GB (1) GB201816369D0 (enExample)
IL (1) IL281599B2 (enExample)
MX (1) MX2021003929A (enExample)
PL (1) PL3864009T3 (enExample)
PT (1) PT3864009T (enExample)
SG (1) SG11202102490TA (enExample)
WO (1) WO2020074461A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202005114D0 (en) * 2020-04-07 2020-05-20 Sareum Ltd Crystalline Forms of a Pharmaceutical Compound
KR20240111312A (ko) 2021-10-25 2024-07-16 카이메라 쎄라퓨틱스 인코포레이티드 Tyk2 분해제 및 이의 용도

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794096A (fr) 1972-08-07 1973-05-16 Lepetit Spa Oxazoles 2,4,5-trisubstitues et leur preparation
GB1497536A (en) 1973-12-17 1978-01-12 Lilly Industries Ltd 2-acylaminooxazoles methods for their preparation and their use
DE19653355A1 (de) 1996-12-20 1998-06-25 Dresden Arzneimittel Neue, antikonvulsiv wirkende Aminoimidazole und Verfahren zu ihrer Herstellung
GB0003154D0 (en) 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
BR0111754A (pt) 2000-06-28 2003-04-29 Astrazeneca Ab Uso de um composto, método para inibir aurora 2 quinase em um animal de sangue quente, composto, e, composição farmacêutica
AU2479702A (en) 2000-10-30 2002-05-15 Janssen Pharmaceutica Nv Tripeptidyl peptidase inhibitors
US7361665B2 (en) 2002-07-09 2008-04-22 Vertex Pharmaceuticals Incorporated Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
ATE465731T1 (de) 2003-10-23 2010-05-15 Ab Science 2-aminoaryloxazol-verbindungen als tyrosinkinase- hemmer
GB0504753D0 (en) 2005-03-08 2005-04-13 Astrazeneca Ab Chemical compounds
CA2623327A1 (en) 2005-10-07 2007-04-19 Kissei Pharmaceutical Co., Ltd. Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
WO2007131953A1 (en) 2006-05-12 2007-11-22 Ab Science A new process for the synthesis of 2-aminoxazole compounds
US20090093452A1 (en) 2006-08-24 2009-04-09 Pfizer Inc. Pyrrole, Thiophene, Furan, Imidazole, Oxazole, and Thiazole Derivatives
GB0709031D0 (en) * 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
US8367706B2 (en) 2007-06-20 2013-02-05 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
EP2278969B1 (en) 2008-04-21 2013-02-13 Merck Sharp & Dohme Corp. Inhibitors of Janus kinases
EP2299816B1 (en) 2008-06-18 2013-11-13 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
EP2310384B1 (en) 2008-07-09 2014-04-09 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
EP2166006A1 (en) 2008-09-18 2010-03-24 Dompe' S.P.A. 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
US20130096104A1 (en) 2010-03-17 2013-04-18 Genentech, Inc. Imidazopyridine compounds, compositions and methods of use
US20130143915A1 (en) 2010-07-01 2013-06-06 Cellzome Limited Triazolopyridines as tyk2 inhibitors
US9062038B2 (en) 2010-08-11 2015-06-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
SG11201401342VA (en) 2011-10-12 2014-09-26 Array Biopharma Inc 5,7-substituted-imidazo[1,2-c]pyrimidines
GB201202027D0 (en) 2012-02-06 2012-03-21 Sareum Ltd Pharmaceutical compounds
ES2566205T3 (es) 2012-03-02 2016-04-11 Sareum Limited Inhibidores de quinasa TYK2
KR101202026B1 (ko) 2012-07-03 2012-11-16 민호현 황토 석부작 제조 방법
HRP20220766T1 (hr) 2012-11-08 2022-09-16 Bristol-Myers Squibb Company Amidom-supstituirani heterociklički spojevi korisni kao modulatori il-12, il-23 i/ili ifn alfa odgovora
BR112016004723B1 (pt) * 2013-09-03 2022-08-30 Sareum Limited Compostos de pirrolidina ou morfolina e composição contendo os mesmos
JP6310767B2 (ja) 2014-05-13 2018-04-11 日本電子株式会社 自動分析装置及びノズル洗浄方法
NO2721710T3 (enExample) 2014-08-21 2018-03-31
GB201617871D0 (en) 2016-10-21 2016-12-07 Sareum Limited Pharmaceutical compounds
GB202005114D0 (en) 2020-04-07 2020-05-20 Sareum Ltd Crystalline Forms of a Pharmaceutical Compound

Also Published As

Publication number Publication date
GB201816369D0 (en) 2018-11-28
PL3864009T3 (pl) 2025-04-22
AU2019359320B2 (en) 2024-04-04
US12187716B2 (en) 2025-01-07
JP7383030B2 (ja) 2023-11-17
IL281599B2 (en) 2024-10-01
SG11202102490TA (en) 2021-04-29
ES3021420T3 (en) 2025-05-26
IL281599A (en) 2021-05-31
IL281599B1 (en) 2024-06-01
DK3864009T3 (da) 2025-03-17
CA3111049A1 (en) 2020-04-16
MX2021003929A (es) 2021-06-04
WO2020074461A1 (en) 2020-04-16
AU2019359320A1 (en) 2021-03-18
JP2022514799A (ja) 2022-02-15
KR102844196B1 (ko) 2025-08-07
CN113056456B (zh) 2023-06-13
KR20210076036A (ko) 2021-06-23
EP3864009A1 (en) 2021-08-18
BR112021006424A2 (pt) 2021-07-06
CN113056456A (zh) 2021-06-29
FI3864009T3 (fi) 2025-03-24
US20210387981A1 (en) 2021-12-16
EP3864009B1 (en) 2025-02-19

Similar Documents

Publication Publication Date Title
IL282487B1 (en) Tyk2 inhibitors and their use
SG11202106520VA (en) Kif18a inhibitors
SI3999506T1 (sl) Zaviralci PARP1
IL268614A (en) Aminotriazolopyridines as kinase inhibitors
IL276269A (en) Aminopyrrolotriazines as kinase inhibitors
SG11202100525SA (en) Pyrrolopyrimidine itk inhibitors
IL283409A (en) tyk2 inhibitors and uses thereof
IL282090B2 (en) TYK2 inhibitors and their uses
CA186350S (en) Vaporizer
IL274207B (en) Aminoimidazopyridazines as kinase inhibitors
IL276013A (en) pi4kiiibeta inhibitors
SG11202102379XA (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
IL281599A (en) TYK2 kinase inhibitors
GB201807845D0 (en) Kinase Inhibitors
IL282941B1 (en) Rock kinase inhibitors
GB201914388D0 (en) Kinase inhibitors
GB201812462D0 (en) Inhibitors
GB201804439D0 (en) Dopamin-b-hydroxylase inhibitors
AU2017904208A0 (en) Novel kinase inhibitors i